MADISON, Wis., Jan. 6, 2025 -- In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro™ antibodies, KIF23 gene – the same tools used by the world's leading Midbody Remnants (MBRs) researchers. This strategic partnership combines eMBR's innovation in detecting MBRs with Axio BioPharma's superior manufacturing and global distribution network, making these proprietary antibodies accessible to scientists globally for the first time.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.